Smoking cannabis can have an immediate effect. It can take an hour or more to feel the effects when eaten. Cannabis can make you feel relaxed, giggly, and hungry, or hallucinate or have a dry mouth. Using more cannabis can result in negative effects including blurred vision, bloodshot eyes, feeling sluggish, difficulty concentrating, slower reflexes, increased heart rate and lower blood pressure, and feelings of paranoia and anxiety.
Cannabis has psychoactive and physiological effects when consumed. The immediate desired effects from consuming cannabis include relaxation and euphoria (the "high" or "stoned" feeling), a general alteration of conscious perception, increased awareness of sensation, increased libido and distortions in the perception of time and space. At higher doses, effects can include altered body image, auditory and/or visual illusions, pseudohallucinations and ataxia from selective impairment of polysynaptic reflexes. In some cases, cannabis can lead to dissociative states such as depersonalization and derealization.
Reproduced with kind permission from the Australian Drug Foundation. References Australian Drug Foundation. Cannabis Facts. Last updated 25 Jan 2012. http://www.druginfo.adf.org.au/drug-facts/cannabis (accessed Jan 2013). Australian Drug Foundation (ADF) Vision: Healthy People, Strong Communities. Mission: Working together to prevent alcohol and other drug problems in communities.Related ArticlesCannabis psychosisUse of cannabis can cause a condition called drug-induced psychosis. Cannabis useCannabis can affect your physical and mental health with heavy cannabis use potentially causing psycCannabis: tolerance and dependenceAfter prolonged use, cannabis is addictive and people using cannabis regularly develop dependence anCannabis: withdrawal and treatmentIf a dependent person stops taking cannabis, they may experience withdrawal symptoms. Cannabis/marijuana: what are the effects?The effect of cannabis on a person depends on many factors including their size, weight and health aAdvertisement
In the mid 1990s, the EU provided subsidization for hemp cultivation of ca. $1,050/ha. This support was instrumental in developing a hemp industry in western Europe. However, no comparable support is available in North America, and indeed those contemplating entering into hemp cultivation are faced with extraordinary costs and/or requirements in connection with licensing, security, THC analysis, and record keeping. Those involved in value-added processing and distribution are also faced with legal uncertainties and the regular threat of idiosyncratic, indeed irrational actions of various governments. Simply displaying a C. sativa leaf on advertising has led to the threat of criminal charges in the last decade in several G8 countries. Attempting to export or import hemp products among countries is presently a most uncertain activity.
To make matters more confusing, nine states (including California, Washington, and Colorado) let residents buy cannabis-based products with or without THC. Nearly two dozen other “medical marijuana states” allow the sale of cannabis, including capsules, tinctures, and other items containing CBD or THC, at licensed dispensaries to people whose doctors have certified that they have an approved condition (the list varies by state but includes chronic pain, PTSD, cancer, autism, Crohn’s disease, and multiple sclerosis). Sixteen more states legalized CBD for certain diseases. But because all these products are illegal according to the federal government, cannabis advocates are cautious. “By and large, the federal government is looking the other way,” says Paul Armentano, deputy director of the Washington, DC–based National Organization for the Reform of Marijuana Laws (NORML), but until federal laws are changed, “this administration or a future one could crack down on people who produce, manufacture, or use CBD, and the law would be on its side.”
Acute effects may include anxiety and panic, impaired attention, and memory (while intoxicated), an increased risk of psychotic symptoms, and possibly an increased risk of accidents if a person drives a motor vehicle while intoxicated. Short-term cannabis intoxication can hinder the mental processes of organizing and collecting thoughts. This condition is known as temporal disintegration. Psychotic episodes are well-documented and typically resolve within minutes or hours. There have been few reports of symptoms lasting longer.
Another clinical trial that involved 139 patients with HIV or AIDS and weight loss found that, compared with placebo, oral dronabinol was associated with a statistically significant increase in appetite after 4 to 6 weeks of treatment. Patients receiving dronabinol tended to have weight stabilization, whereas patients receiving placebo continued to lose weight.
Hemp is the fiber and seed part of the Cannabis Sativa L. plant, opposed to the flower part of the plant which is “legally considered” marijuana. The fiber and seeds are incredible valuable and is why hemp is often called a “cash crop”. Hemp is a very hearty plant and grows very quickly in very diverse soil conditions. Cultivation of hemp for industrial purposes has been done by many civilizations for over 12,000 years. Industrial hemp was the desired fiber used to manufacture rope, canvas, paper, and clothing until alternative textiles and synthetics for these purposes were discovered. Although China has been the largest hemp producer over the years, other countries such as Australia and Canada are catching up. It has been illegal for anyone to grow hemp in the United States as hemp is illegal under the marijuana prohibition act but Colorado has changed the laws and paved the way for industrial hemp production again in the United States(see hemp history). Now hemp oils, hemp plastics, hemp building materials and many hemp fiber products can be seen and purchased on the market. Hemp is truly an amazing plant with the potential to help “green up” many industries.
There are thousands of unique varieties of hemp. The cultivars used for CBD oil contain significantly higher concentrations of CBD than others. Using these uniquely potent plants, it is possible to extract cannabis oil that contains significant levels of cannabidiol, as well as essential vitamins, minerals, fatty acids, terpenes, flavonoids, and other non-psychoactive cannabinoids.
On Oct. 22 and 23, KDA participated in four informational meetings about Industrial Hemp in Manhattan, Salina, Colby and Garden City hosted by Kansas Farmers Union. The presentation shared by KDA at those meetings can be seen here: KDA Industrial Hemp Presentation. Information on the event, including the video of the guest presenter, can be found on the Kansas Farmers Union website.
No ongoing clinical trials of Cannabis as a treatment for cancer in humans were identified in a PubMed search. The only published trial of any cannabinoid in patients with cancer is a small pilot study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma multiforme, which demonstrated no significant clinical benefit.[19,20] In a trial (NCT02255292) conducted in Israel, oral cannabidiol (CBD) was investigated as a single salvage agent for recurrent solid tumors. The study was projected to be completed in 2015; however, no results have been published. A small exploratory phase II study (GWCA1208 Part A [NCT01812603]) was conducted in the United Kingdom that used nabiximols, a 1:1 ratio of THC:CBD in a Cannabis-based medicinal extract oromucosal spray, in conjunction with temozolomide in treating patients with recurrent glioblastoma multiforme. The study enrolled 21 patients. Final results have not been published.
In addition, both plant-derived and endogenous cannabinoids have been studied for anti-inflammatory effects. A mouse study demonstrated that endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic inflammation. As a result, a hypothesis that phytocannabinoids and endocannabinoids may be useful in the risk reduction and treatment of colorectal cancer has been developed.[27-30]
Researchers in New Zealand have studied whether cannabis can be used to treat severe motor and vocal tics in those suffering from Tourette syndrome. The study concluded that subjects who took a controlled THC-CBD medicated spray showed marked improvement in the frequency and severity of motor and vocal tics post-treatment. Although the study is only a small clinical trial, it is one of the first to specifically analyze the effects of cannabis on Tourette syndrome.
Fatty Acids. The quality of an oil or fat is most importantly determined by its fatty acid composition. Hemp is of high nutritional quality because it contains high amounts of unsaturated fatty acids, mostly oleic acid (C18:1, 10%–16%), linoleic acid (C18:2, 50%–60%), alpha-linolenic acid (C18:3, 20%–25%), and gamma-linolenic acid (C18:3, 2%–5%) (Fig. 37). Linoleic acid and alpha-linolenic acid are the only two fatty acids that must be ingested and are considered essential to human health (Callaway 1998). In contrast to shorter-chain and more saturated fatty acids, these essential fatty acids do not serve as energy sources, but as raw materials for cell structure and as precursors for biosynthesis for many of the body’s regulatory biochemicals. The essential fatty acids are available in other oils, particularly fish and flaxseed, but these tend to have unpleasant flavors compared to the mellow, slightly nutty flavor of hempseed oil. While the value of unsaturated fats is generally appreciated, it is much less well known that the North American diet is serious nutritionally unbalanced by an excess of linoleic over alpha-linonenic acid. In hempseed, linoleic and alpha-linolenic occur in a ratio of about 3:1, considered optimal in healthy human adipose tissue, and apparently unique among common plant oils (Deferne and Pate 1996). Gamma-linolenic acid or GLA is another significant component of hemp oil (1%–6%, depending on cultivar). GLA is a widely consumed supplement known to affect vital metabolic roles in humans, ranging from control of inflammation and vascular tone to initiation of contractions during childbirth. GLA has been found to alleviate psoriasis, atopic eczema, and mastalgia, and may also benefit cardiovascular, psychiatric, and immunological disorders. Ageing and pathology (diabetes, hypertension, etc.) may impair GLA metabolism, making supplementation desirable. As much as 15% of the human population may benefit from addition of GLA to their diet. At present, GLA is available in health food shops and pharmacies primarily as soft gelatin capsules of borage or evening primrose oil, but hemp is almost certainly a much more economic source. Although the content of GLA in the seeds is lower, hemp is far easier to cultivate and higher-yielding. It is important to note that hemp is the only current natural food source of GLA, i.e. not requiring the consumption of extracted dietary supplements. There are other fatty acids in small concentrations in hemp seed that have some dietary significance, including stearidonic acid (Callaway et al. 1996) and eicosenoic acid (Mölleken and Theimer 1997). Because of the extremely desirable fatty acid constitution of hemp oil, it is now being marketed as a dietary supplement in capsule form (Fig. 38).
All of this makes CBD remarkably difficult for even the most dedicated health care providers to manage safely. Dr. Kelly Knupp, an associate professor of pediatrics and neurology at the University of Colorado, and the director of the Dravet Syndrome program at Children’s Hospital Colorado, said families of epileptic children have tried to bring CBD oils to the hospital for testing. “They’re just concerned that they don’t know exactly who’s growing [the hemp],” Knupp said. “They know it’s not being regulated.” But because CBD is a Schedule I controlled substance, high-tech, regulated laboratories, like those at the University of Colorado, can’t accept, store, or test CBD oils, lest they risk prosecution. “There is no such lab that can take that product,” Knupp said, which leaves any testing up to the unregulated testing centers that cater to the cannabis industry.
Several of the cannabinoids are reputed to have medicinal potential: THC for glaucoma, spasticity from spinal injury or multiple sclerosis, pain, inflammation, insomnia, and asthma; CBD for some psychological problems. The Netherlands firm HortaPharm developed strains of Cannabis rich in particular cannabinoids. The British firm G.W. Pharmaceuticals acquired proprietary access to these for medicinal purposes, and is developing medicinal marijuana. In the US, NIH (National Institute of Health) has a program of research into medicinal marijuana, and has supplied a handful of individuals for years with maintenance samples for medical usage. The American Drug Enforcement Administration is hostile to the medicinal use of Cannabis, and for decades research on medicinal properties of Cannabis in the US has been in an extremely inhospitable climate, except for projects and researchers concerned with curbing drug abuse. Synthetic preparations of THC—dronabinol (Marinol®) and nabilone (Cesamet®)—are permitted in some cases, but are expensive and widely considered to be less effective than simply smoking preparations of marijuana. Relatively little material needs to be cultivated for medicinal purposes (Small 1971), although security considerations considerably inflate costs. The potential as a “new crop” for medicinal cannabinoid uses is therefore limited. However, the added-value potential in the form of proprietary drug derivatives and drug-delivery systems is huge. The medicinal efficacy of Cannabis is extremely controversial, and regrettably is often confounded with the issue of balancing harm and liberty concerning the proscriptions against recreational use of marijuana. This paper is principally concerned with the industrial uses of Cannabis. In this context, the chief significance of medicinal Cannabis is that, like the issue of recreational use, it has made it very difficult to rationally consider the development of industrial hemp in North America for purposes that everyone should agree are not harmful.
Success stories like Oliver’s are everywhere, but there’s not a lot of data to back up those results. That’s because CBD comes from cannabis and, like nearly all other parts of the plant, is categorized by the Drug Enforcement Agency (DEA) as a Schedule 1 drug—the most restrictive classification. (Others on that list: heroin, Ecstasy, and peyote.) This classification, which cannabis advocates have tried for years to change, keeps cannabis-derived products, including CBD, from being properly studied in the U.S.
Another field in which CBD is creating a buzz is in the area of mood disorders like anxiety and depression. Both conditions have been treated with a variety of medications, courtesy of Big Pharma, that have had varying levels of success. Again, the long list of side effects can be off-putting to someone who just wants to get through the day without the sweaty tension of anxiety or the gray haze of depression.
Heavy, long term exposure to marijuana may have biologically-based physical, mental, behavioral and social health consequences and may be "associated with diseases of the liver (particularly with co-existing hepatitis C), lungs, heart, and vasculature". It is recommended that cannabis use be stopped before and during pregnancy as it can result in negative outcomes for both the mother and baby. However, maternal use of marijuana during pregnancy does not appear to be associated with low birth weight or early delivery after controlling for tobacco use and other confounding factors. A 2014 review found that while cannabis use may be less harmful than alcohol use, the recommendation to substitute it for problematic drinking is premature without further study. Other side effects include cannabinoid hyperemesis syndrome.
Recent European Commission proposals to change its subsidy regime for hemp contained the following negative evaluation of hemp seed: “The use of hemp seed ... would, however, even in the absence of THC, contribute towards making the narcotic use of cannabis acceptable... In this light, subsidy will be denied producers who are growing grain for use in human nutrition and cosmetics.”
There is a general inverse relationship in the resin of Cannabis between the amounts of THC present and the amount of the other principal cannabinoid, CBD. Whereas most drug strains contain primarily THC and little or no CBD, fiber and oilseed strains primarily contain CBD and very little THC. CBD can be converted to THC by acid catalyzed cyclization, and so could serve as a starting material for manufacturing THC. In theory, therefore, low-THC cultivars do not completely solve the problem of drug abuse potential. In practice, however, the illicit drug trade has access to easier methods of synthesizing THC or its analogues than by first extracting CBD from non-drug hemp strains.
THC, an intoxicating and illegal substance, is responsible for causing marijuana users to get “high.” Unlike THC, CBD is non-psychoactive because it does not act on the same pathways as THC. Thus, it is impossible to get “high” by smoking or ingesting CBD or CBD oil extracted from industrial hemp plants, as they only have minuscule traces of THC (<0.3%).
Pinfold Consulting. 1998. (G. Pinfold Consulting Economists Ltd. and J. White, InfoResults Ltd.). A maritime industrial hemp product marketing study. Prepared for Nova Scotia Agriculture and Marketing (Marketing and Food Industry Development), and New Brunswick Agriculture & Rural Development (Marketing and Business Development). agri.gov.ns.ca/pt/agron/hemp/hempms.htm
This guide is an introduction to anyone looking to inform themselves about the reality of cannabis. It covers basic information about the marijuana plant, cannabis preparations, and the crucial elements of plant anatomy and science. This guide to marijuana also gives an overview of the most popular medical and recreational uses of cannabis. It offers a survey of the most important medical cannabis research while highlighting emerging trends in the legal cannabis market. The guide also introduces those new to cannabis to the many ways to consume marijuana, and much more.
Breeding for low THC cultivars in Europe has been reviewed by Bócsa (1998), Bócsa and Karus (1998), and Virovets (1996). Some researchers have claimed to have produced essentially THC-free strains, although at present no commercial cultivar seems to be 100% free of THC. THC content has proven to be more easily reduced in monoecious than in dioecious varieties. It should be possible to select THC-free strains, and there has been speculation that genetic engineering could be helpful in this regard. As a strategic economic and political tactic, France has been attempting for several years to have the European Union (EU) adopt legislation forbidding the cultivation of industrial hemp cultivars with more than 0.1% THC, which would mean that primarily French varieties would have to be cultivated in Europe. However, the Canadian government has found that some French material has proven to be excessively high in THC.
The confusion compounds when one realizes that in today’s popular lexicon, the terms indica, sativa, and hybrid tend to indicate a set of effects, rather than the taxonomy of a particular strain. But that’s just as well. Most marijuana strains today, especially those under commercial cultivation, are genetic hybrids. Only a handful of pure, or “landrace” cannabis strains are in circulation.
In the end, companies like HempMedsPx are asking consumers simply to trust them. CBD oils are never subjected to systematic testing by any U.S. regulatory body. The FDA regulates all pharmaceutical labs in the country. But cannabis labs like the ones that HempMedsPx and others use are not, because cannabis is not federally recognized as a legal drug.
"CBD increases the circulating levels of your natural endocannabinoids, which, in turn, interact with your cannabinoid receptors," Bonn-Miller says. "CBD has also been shown to interact with serotonin receptors, and that may be part of why it has some beneficial effects on anxiety. It also interacts with some pain receptors, which may be why we're starting to see effects on pain and inflammation."
A mixture of fiberglass, hemp fiber, kenaf, and flax has been used since 2002 to make composite panels for automobiles. The choice of which bast fiber to use is primarily based on cost and availability. Various car makers are beginning to use hemp in their cars, including Audi, BMW, Ford, GM, Chrysler, Honda, Iveco, Lotus, Mercedes, Mitsubishi, Porsche, Saturn, Volkswagen and Volvo. For example, the Lotus Eco Elise and the Mercedes C-Class both contain hemp (up to 20 kg in each car in the case of the latter).